DK1232260T3 - Polymorfi i det humane MDR-1-gen og anvendelser deraf - Google Patents

Polymorfi i det humane MDR-1-gen og anvendelser deraf

Info

Publication number
DK1232260T3
DK1232260T3 DK00972654T DK00972654T DK1232260T3 DK 1232260 T3 DK1232260 T3 DK 1232260T3 DK 00972654 T DK00972654 T DK 00972654T DK 00972654 T DK00972654 T DK 00972654T DK 1232260 T3 DK1232260 T3 DK 1232260T3
Authority
DK
Denmark
Prior art keywords
mdr
vectors
proteins
polynucleotides
gene
Prior art date
Application number
DK00972654T
Other languages
English (en)
Inventor
Ulrich Brinkmann
Sven Hoffmeyer
Michel Eichelbaum
Ivar Roots
Original Assignee
Epidauros Biotechnologie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epidauros Biotechnologie Ag filed Critical Epidauros Biotechnologie Ag
Application granted granted Critical
Publication of DK1232260T3 publication Critical patent/DK1232260T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
DK00972654T 1999-07-30 2000-07-28 Polymorfi i det humane MDR-1-gen og anvendelser deraf DK1232260T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99114938 1999-07-30
EP00103361 2000-02-22
PCT/EP2000/007314 WO2001009183A2 (en) 1999-07-30 2000-07-28 Polymorphisms in the human mdr-1 gene and applications thereof

Publications (1)

Publication Number Publication Date
DK1232260T3 true DK1232260T3 (da) 2008-02-04

Family

ID=26070560

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00972654T DK1232260T3 (da) 1999-07-30 2000-07-28 Polymorfi i det humane MDR-1-gen og anvendelser deraf

Country Status (20)

Country Link
US (1) US20050227249A1 (da)
EP (1) EP1232260B1 (da)
JP (2) JP2003510021A (da)
KR (1) KR100814188B1 (da)
AT (1) ATE373710T1 (da)
AU (1) AU1131901A (da)
BG (1) BG65988B1 (da)
CA (2) CA2697207A1 (da)
CZ (1) CZ2002329A3 (da)
DE (1) DE60036487T2 (da)
DK (1) DK1232260T3 (da)
EE (1) EE200200049A (da)
ES (1) ES2292481T3 (da)
HR (1) HRP20020093B1 (da)
HU (1) HUP0201997A3 (da)
MX (1) MXPA02001094A (da)
NO (2) NO330680B1 (da)
PL (1) PL354034A1 (da)
SK (1) SK1502002A3 (da)
WO (1) WO2001009183A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001231550A1 (en) * 2000-11-29 2002-06-11 Epidauros Biotechnologie Ag Use of mdr-1 inducers for treating or preventing diseases
JP2004524822A (ja) * 2000-11-29 2004-08-19 エピダウロス バイオテクノロジー アクツィエンゲゼルシャフト Ｍｄｒ１遺伝子多型に基づいて不全症を発症する危険性が増大した個体を診断する方法
US6790621B2 (en) 2001-01-12 2004-09-14 Washington State University Research Foundation Method of detecting ivermectin sensitivity in a canine subject by identifying a mutation in a mdr1-encoding sequence
WO2003025174A2 (en) * 2001-09-06 2003-03-27 Bayer Healthcare Ag Regulation of human mrp1-like protein
EP1340818A1 (en) 2002-02-27 2003-09-03 Epigenomics AG Method and nucleic acids for the analysis of a colon cell proliferative disorder
WO2004042081A1 (de) * 2002-11-04 2004-05-21 Charité-Universitätsme Dizin Berlin Spezifische haplotypen des mdr1-gens und deren anwendung in der diagnose und therapie
US8030033B2 (en) 2004-05-12 2011-10-04 Max-Planck-Gesellschaft Zur Forderung Der Wissenshaften E.V. Polymorphisms in ABCB1 associated with a lack of clinical response to medicaments
CA2611188A1 (en) * 2005-06-13 2006-12-21 Laurent Essioux Mdr1 snp in acute rejection
JP2008545446A (ja) * 2005-06-13 2008-12-18 エフ．ホフマン−ラ ロシュ アーゲー 急性拒絶反応に関連するｉｍｐｄｈ２ｓｎｐ
WO2006133840A1 (en) * 2005-06-13 2006-12-21 F.Hoffmann-La Roche Ag Il10 snp associated with acute rejection
WO2007058896A2 (en) * 2005-11-10 2007-05-24 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment
WO2008151803A2 (en) 2007-06-12 2008-12-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. New polymorphisms in abcb1 associated with a lack of clinical response to medicaments
KR101033840B1 (ko) * 2011-03-08 2011-05-16 (주)제일엔지니어링건축사사무소 공동주택용 입상관 연결구조
US20180365372A1 (en) * 2017-06-19 2018-12-20 Jungla Inc. Systems and Methods for the Interpretation of Genetic and Genomic Variants via an Integrated Computational and Experimental Deep Mutational Learning Framework

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) * 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5206352A (en) * 1986-03-28 1993-04-27 Board Of Trustees Of The University Of Illinois Compositions for clones containing DNA sequences associated with multidrug resistance in human cells
US5851819A (en) * 1987-06-16 1998-12-22 National Institutes Of Health Vectors carrying MDR1 cDNA which confer multidrug resistance on transduced cells
US5928637A (en) * 1987-06-16 1999-07-27 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods of inducing multidrug resistance using human MDR1 cDNA
JPH02100680A (ja) * 1988-10-05 1990-04-12 Suntory Ltd ヒト正常細胞由来ｍｄｒ関連遺伝子
US5399483A (en) * 1989-03-30 1995-03-21 Suntory Limited Expression of MDR-related gene in yeast cell
US5856104A (en) * 1996-10-28 1999-01-05 Affymetrix, Inc. Polymorphisms in the glucose-6 phosphate dehydrogenase locus
US5830697A (en) * 1997-01-21 1998-11-03 The Board Of Trustees Of The Leland Stanford Junior University P-glycoprotein mutant resistant to cyclosporin modulation

Also Published As

Publication number Publication date
US20050227249A1 (en) 2005-10-13
BG106362A (bg) 2002-09-30
HRP20020093A2 (en) 2004-06-30
MXPA02001094A (es) 2003-07-21
AU1131901A (en) 2001-02-19
KR20020059347A (ko) 2002-07-12
KR100814188B1 (ko) 2008-03-17
CA2697207A1 (en) 2001-02-08
EP1232260B1 (en) 2007-09-19
JP2011142909A (ja) 2011-07-28
SK1502002A3 (en) 2002-07-02
NO20100798L (no) 2002-03-26
NO330680B1 (no) 2011-06-06
EE200200049A (et) 2003-04-15
BG65988B1 (bg) 2010-08-31
PL354034A1 (en) 2003-12-15
HUP0201997A3 (en) 2005-01-28
NO20020470L (no) 2002-03-26
CA2376666A1 (en) 2001-02-08
JP2003510021A (ja) 2003-03-18
CA2376666C (en) 2010-05-25
DE60036487T2 (de) 2008-06-19
HUP0201997A2 (en) 2002-09-28
DE60036487D1 (de) 2007-10-31
WO2001009183A3 (en) 2002-03-28
CZ2002329A3 (cs) 2002-07-17
NO20020470D0 (no) 2002-01-29
ES2292481T3 (es) 2008-03-16
HRP20020093B1 (en) 2011-02-28
ATE373710T1 (de) 2007-10-15
WO2001009183A2 (en) 2001-02-08
EP1232260A2 (en) 2002-08-21

Similar Documents

Publication Publication Date Title
Vertegaal Signalling mechanisms and cellular functions of SUMO
Gallegos et al. Chromatin regulation of neuronal maturation and plasticity
DK1232260T3 (da) Polymorfi i det humane MDR-1-gen og anvendelser deraf
Sun et al. Functional and molecular expression of the proton-coupled oligopeptide transporters in spleen and macrophages from mouse and human
WO2004053079A3 (en) Compositions, splice variants and methods relating to ovarian specific genes and proteins
BRPI0510206A (pt) método de identificação de fenótipo, célula isolada, métodos de identificação de agentes, agentes, agentes terapêuticos, método de avaliação de agente terapêutico, composição farmacêutica, métodos de tratamento, prevenção ou melhoria de disfunções e métodos de modulação
NO20021146L (no) Polymorfier i det humane CYP3A7 og CYP3A7 gener og deres anvendelse i diagnostikk og terapeutiske applikasjoner
Chang et al. rAAV-CRISPRa therapy corrects Rai1 haploinsufficiency and rescues selective disease features in Smith-Magenis syndrome mice
DE60328959D1 (de) Auswahl von Tieren für gewünschte genotypische und potentielle phänotypische Eigenschaften auf der Basis eines einzelnen Nukleotidpolymorphismus (SNP) im Intron 3 des IGF2-Gens
Pang et al. High-throughput sequencing offers new insights into 5-hydroxymethylcytosine
Gronowicz Personalized medicine: Promises and pitfalls
WO2004050860A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
Tholey et al. We are not alone: the iMOP initiative and its roles in a biology-and disease-driven human proteome project
DK1272663T3 (da) Polymorfier i det humane CYP2B6-gen og deres anvendelse ved diagnostiske og terapeutiske anvendelser
WO2004013311A3 (en) Compositions and methods relating to ovarian specific genes and proteins
DE50312502D1 (de) Screeningverfahren zum identifizieren protektiver substanzen für die behandlung neurodegenerativer und/oder ischämischer erkrankungen
WO2004050858A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
Holcomb et al. GRHD PLANNING COMMITTEE
Long et al. The Role of Protocadherin γ in Adult Sensory Neurons and Skin Reinnervation
ATE541040T1 (de) Pim-3 kinase als ziel für type 2 diabetes mellitus
NAFEA et al. Study of Vascular Endothelial Growth Factor Gene Polymorphism in Acute Myeloid Leukemia Patients
Fluman INVESTIGATING THE COUPLING MECHANISM IN THE E. COLI MULTIDRUG TRANSPORTER, MdfA, BY FLUORESCENCE SPECTROSCOPY
TH62387A (th) วิธีการระบุเอนไซม์ซึ่งมุ่งเป้าหมายที่เนื้องอก
WO2005005647A3 (en) Compositions, splice variants and methods relating to ovarian specific genes and proteins
WO2005027713A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins